Clinical Scorecard: New Sublocade Label Allows for Faster Treatment Initiation
At a Glance
| Category | Detail |
|---|---|
| Condition | Opioid Use Disorder (OUD) |
| Key Mechanisms | Buprenorphine extended-release injection with rapid initiation protocol. |
| Target Population | Patients with moderate to severe opioid use disorder. |
| Care Setting | Clinical practice with a focus on treatment induction. |
Key Highlights
- FDA approved label changes for Sublocade to allow rapid initiation protocol.
- Rapid initiation protocol reduces treatment induction period from 1 week to 1 hour.
- Participants in rapid initiation group had higher retention rates for second injection.
- Sublocade can now be administered subcutaneously in multiple sites.
- Common adverse reactions include constipation, headache, and injection site pain.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of moderate to severe opioid use disorder.
Management
- Use Sublocade as part of a comprehensive treatment plan including counseling.
Monitoring & Follow-up
- Monitor for serious harm or death if administered intravenously.
Risks
- Risk of serious harm or death if administered intravenously.
Patient & Prescribing Data
Patients stabilized on transmucosal buprenorphine.
Rapid initiation protocol improves likelihood of receiving subsequent injections.
Clinical Best Practices
- Implement rapid initiation protocol to enhance treatment access.
- Ensure comprehensive treatment plans that include psychosocial support.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
